Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in mild to severe Alzheimer's Disease
NCT05074498Phase 2Completed
- Sponsor
- TrueBinding Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TB006 in Alzheimer's disease (AD), sponsored by TrueBinding Inc.. Started Oct 2021; status: completed.
02
Drugs
TB006
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05074498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074498.